keyword
MENU ▼
Read by QxMD icon Read
search

Ccrcc

keyword
https://www.readbyqxmd.com/read/28819401/identification-and-validation-of-soluble-carrier-family-expression-signature-for-predicting-poor-outcome-of-renal-cell-carcinoma
#1
Wan Fangning, Ma Chunguang, Zhang Hailiang, Shi Guohai, Zhu Yao, Dai Bo, Shen Yijun, Zhu Yiping, Ye Dingwei
The soluble carrier (SLC) family plays an important role in cell metabolism. The purpose of the current study was to screen SLCs as potential prognostic factors in clear cell renal cell carcinoma (ccRCC). A total of 509 patients with ccRCC from The Cancer Genome Atlas (TCGA) cohort were enrolled in this study. The expression profile of SLCs was obtained from the TCGA RNAseq database. Metadata of the TCGA cohort, including age, sex, TNM stage, tumor grade, American Joint Committee on Cancer stage, laterality, and overall survival, were collected...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28819235/expression-of-long-non-coding-rna-mfi2-as1-is-a-strong-predictor-of-recurrence-in-sporadic-localized-clear-cell-renal-cell-carcinoma
#2
Ronan Flippot, Roger Mouawad, Jean-Philippe Spano, Morgan Rouprêt, Eva Compérat, Marc-Olivier Bitker, Jérôme Parra, Christophe Vaessen, Frederick Allanic, Quentin Manach, Nizar M Tannir, David Khayat, Xiaoping Su, Gabriel G Malouf
Prediction of recurrence is a challenge for the development of adjuvant treatments in clear-cell renal cell carcinoma (ccRCC). In these tumors, expression of long non-coding RNAs (lncRNAs) are deregulated and closely associated with prognosis. Thus, we aimed to predict ccRCC recurrence risk using lncRNA expression. We identified prognostic lncRNAs in a training set of 351 localized ccRCCs from The Cancer Genome Atlas and validated lncRNA-based recurrence classification in an independent cohort of 167 localized ccRCCs...
August 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28815885/novel-landscape-of-hla-g-isoforms-expressed-in-clear-cell-renal-cell-carcinoma-patients
#3
Diana Tronik-Le Roux, Julie Renard, Jérôme Vérine, Victor Renault, Emmanuel Tubacher, Joel LeMaoult, Nathalie Rouas-Freiss, Jean-François Deleuze, François Desgrandschamps, Edgardo D Carosella
Immune-checkpoints are powerful inhibitory molecules that promote tumor survival. Their blockade is now recognized as providing effective therapeutic benefit against cancer. HLA-G, a recently identified immune checkpoint, has been detected in many types of primary tumors and metastases, in malignant effusions as well as on tumor-infiltrating cells, particularly in patients with clear cell renal cell carcinoma (ccRCC). Here, in order to define a possible anti-cancer therapy, we used a molecular approach based on an unbiased strategy that combines transcriptome determination and immunohistochemical labeling, to analyze in-depth, the HLA-G isoforms expressed in these tumors...
August 16, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28812986/epigenome-aberrations-emerging-driving-factors-of-the-clear-cell-renal-cell-carcinoma
#4
REVIEW
Ali Mehdi, Yasser Riazalhosseini
Clear cell renal cell carcinoma (ccRCC), the most common form of Kidney cancer, is characterized by frequent mutations of the von Hippel-Lindau (VHL) tumor suppressor gene in ~85% of sporadic cases. Loss of pVHL function affects multiple cellular processes, among which the activation of hypoxia inducible factor (HIF) pathway is the best-known function. Constitutive activation of HIF signaling in turn activates hundreds of genes involved in numerous oncogenic pathways, which contribute to the development or progression of ccRCC...
August 16, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28811845/role-of-contrast-enhancement-and-corrected-attenuation-values-of-renal-tumors-in-predicting-renal-cell-carcinoma-rcc-subtypes-protocol-for-a-triphasic-multi-slice-computed-tomography-ct-procedure
#5
Ersen Ertekin, Akın Soner Amasyalı, Bulent Erol, Saim Acikgozoglu, Faruk Kucukdurmaz, Alaaddin Nayman, Haluk Erol
BACKGROUND: To distinguish RCC subtypes based on contrast enhancement features of CT images. MATERIAL/METHODS: In total, 59 lesions from 57 patients were included. All patients underwent multi-slice CT imaging with a triphasic protocol, which included non-contrast, corticomedullary, nephrographic and urographic phases. Contrast enhancement features of renal masses were evaluated in terms of CT attenuation values (AV) and differences in contrast density; the aorta or renal parenchyma were evaluated based on corrected or relative values...
2017: Polish Journal of Radiology
https://www.readbyqxmd.com/read/28809959/expression-and-activity-of-angiotensin-regulating-enzymes-is-associated-with-prognostic-outcome-in-clear-cell-renal-cell-carcinoma-patients
#6
Peio Errarte, Maider Beitia, Itxaro Perez, Lorea Manterola, Charles H Lawrie, Jon Danel Solano-Iturri, Julio Calvete-Candenas, Miguel Unda, José I López, Gorka Larrinaga
The discovery of the intrarenal renin-angiotensin system (iRAS), which regulates angiogenesis, cell differentiation and proliferation, has opened new perspectives in the knowledge of kidney carcinogenesis. In this study we analyzed the immunohistochemical expression and fluorimetric activity of four key peptidases of iRAS in tumor tissue (n = 144) and serum samples (n = 128) from patients with renal neoplasms. Neutral endopeptidase (NEP/CD10), Angiotensin-converting enzyme-2 (ACE2), and aminopeptidase A (APA) were expressed in tumor cells whilst Angiotensin-converting enzyme (ACE) was expressed in the endothelial cells of intratumor blood vessels...
2017: PloS One
https://www.readbyqxmd.com/read/28803448/microvascular-and-lymphovascular-tumor-invasion-are-associated-with-poor-prognosis-and-metastatic-spread-in-renal-cell-carcinoma-a-validation-study-in-clinical-practice
#7
Jens Bedke, Johannes Heide, Silvia Ribback, Steffen Rausch, Michela de Martino, Marcus Scharpf, Andrea Haitel, Uwe Zimmermann, Maik Pechoel, Hussam Alkhayyat, Shahrokh F Shariat, Frank Dombrowski, Arnulf Stenzl, Martin Burchardt, Tobias Klatte, Nils Kroeger
OBJECTIVE: To validate microvascular (MVI) and lymphovascular (LVI) invasion as a prognostic factor in renal cell carcinoma patients (pts.) MATERIALS AND METHODS: Data of patients with RCC who underwent radical or nephron sparing surgery were prospectively collected from three academic centers. The occurrence of MVI and LVI was determined with standard staining protocols by experienced pathologists at the time of diagnosis. The association of MVI and LVI with clinicopathological data, metastatic spread and cancer-specific survival (CSS) was evaluated with Fisher's exact tests, binary logistic regression analyses and univariable and multivariable Cox proportional hazard regression models...
August 13, 2017: BJU International
https://www.readbyqxmd.com/read/28789930/commentary-on-an-integrated-metabolic-atlas-of-clear-cell-renal-cell-carcinoma-hakimi-aa-reznik-e-lee-ch-creighton-cj-brannon-ar-luna-a-aksoy-ba-liu-em-shen-r-lee-w-chen-y-stirdivant-sm-russo-p-chen-yb-tickoo-sk-reuter-ve-cheng-eh-sander-c-hsieh-jj-cancer-cell
#8
Byron H Lee
Dysregulated metabolism is a hallmark of cancer, manifested through alterations in metabolites. We performed metabolomic profiling on 138 matched clear cell renal cell carcinoma (ccRCC)/normal tissue pairs and found that ccRCC is characterized by broad shifts in central carbon metabolism, one-carbon metabolism, and antioxidant response. Tumor progression and metastasis were associated with metabolite increases in glutathione and cysteine/methionine metabolism pathways. We develop an analytic pipeline and visualization tool (metabolograms) to bridge the gap between TCGA transcriptomic profiling and our metabolomic data, which enables us to assemble an integrated pathway-level metabolic atlas and to demonstrate discordance between transcriptome and metabolome...
August 5, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28781191/phase-i-study-of-dalteparin-in-combination-with-sunitinib-in-patients-with-metastatic-clear-cell-renal-carcinoma
#9
Madelon Q Wentink, Henk M W Verheul, Sumanta K Pal, Saby George, Johannes Voortman, Pongwut Danchaivijitr, Remi Adelaiye, Diane Poslinski, Adrienne Groman, Alan Hutson, Roberto Pili
BACKGROUND: Based on the tumor-driven concomitant activation of angiogenesis and coagulation we conducted a phase I combination study of sunitinib with the low molecular weight heparin dalteparin in patients with metastatic clear cell renal cell carcinoma (ccRCC). MATERIALS AND METHODS: Patients received standard treatment with sunitinib (50 mg daily, 4 weeks on, 2 weeks off). During the second week of no sunitinib in the first cycle (week 6) patients received dalteparin monotherapy (in escalating doses)...
July 14, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28778070/the-association-between-renal-sinus-fat-area-and-the-progression-free-survival-in-chinese-non-metastatic-clear-cell-renal-cell-carcinoma-patients
#10
Haichao Huang, Shi Chen, Wei Yu, Zirong Ye, Wei Li, Jinchun Xing, Xiurong Wu
In this retrospective study, we evaluated the association between renal sinus fat area (RSFA) and survival in 268 Chinese non-metastatic clear-cell renal cell carcinoma (ccRCC) patients. Patients with high RSFA exhibited better progression-free survival than those with low RSFA in both univariable (HR: 0.240; 95% CI: 0.119-0.482; p < 0.001) and multivariable (HR: 0.432; 95% CI: 0.369-2.749; p = 0.027) analyses. A propensity-score matched (PSM) analysis using Kaplan-Meier curves confirmed our findings (log-rank test; p = 0...
July 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/28768909/addressing-metabolic-heterogeneity-in-clear-cell-renal-cell-carcinoma-with-quantitative-dixon-mri
#11
Yue Zhang, Durga Udayakumar, Ling Cai, Zeping Hu, Payal Kapur, Eun-Young Kho, Andrea Pavía-Jiménez, Michael Fulkerson, Alberto Diaz de Leon, Qing Yuan, Ivan E Dimitrov, Takeshi Yokoo, Jin Ye, Matthew A Mitsche, Hyeonwoo Kim, Jeffrey G McDonald, Yin Xi, Ananth J Madhuranthakam, Durgesh K Dwivedi, Robert E Lenkinski, Jeffrey A Cadeddu, Vitaly Margulis, James Brugarolas, Ralph J DeBerardinis, Ivan Pedrosa
BACKGROUND: Dysregulated lipid and glucose metabolism in clear cell renal cell carcinoma (ccRCC) has been implicated in disease progression, and whole tumor tissue-based assessment of these changes is challenged by the tumor heterogeneity. We studied a noninvasive quantitative MRI method that predicts metabolic alterations in the whole tumor. METHODS: We applied Dixon-based MRI for in vivo quantification of lipid accumulation (fat fraction [FF]) in targeted regions of interest of 45 primary ccRCCs and correlated these MRI measures to mass spectrometry-based lipidomics and metabolomics of anatomically colocalized tissue samples isolated from the same tumor after surgery...
August 3, 2017: JCI Insight
https://www.readbyqxmd.com/read/28767410/orellanine-specifically-targets-renal-clear-cell-carcinoma
#12
Lisa Buvall, Heidi Hedman, Alina Khramova, Deman Najar, Lovisa Bergwall, Kerstin Ebefors, Carina Sihlbom, Sven Lundstam, Anders Herrmann, Hanna Wallentin, Emelie Roos, Ulf A Nilsson, Martin Johansson, Jan Törnell, Börje Haraldsson, Jenny Nyström
Renal cell carcinoma (RCC), arising from the proximal tubule in the kidney, accounts for approximately 85% of kidney cancers and causes over 140,000 annual deaths worldwide. In the last decade, several new therapies have been identified for treatment of metastatic RCC. Although these therapies increase survival time compared to standard care, none of them has curative properties. The nephrotoxin orellanine specifically targets proximal tubular epithelial cells, leaving other organs unaffected. We therefore hypothesized that the selective toxicity of orellanine extends to clear cell RCC (ccRCC) cells since they emanate from proximal tubular cells...
July 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28765116/bap1-and-pbrm1-determinants-of-tumor-grade-and-mtor-activation-in-vhl-deficient-mouse-models-of-renal-cell-carcinoma
#13
Janet Y Leung, William Y Kim
Large genome sequencing efforts have identified frequent mutations in the histone-modifying and chromatin-remodeling genes BAP1 and PBRM1 in clear cell renal cell carcinoma (ccRCC). In this issue of Cancer Discovery, Gu and colleagues model these genetic events in mice and report that dual inactivation of Vhl with either Bap1 or Pbrm1 results in faithful genetically engineered murine models of ccRCC. Moreover, their work establishes that Bap1 and Pbrm1 are determinants of tumor grade and mTORC1 activation and provocatively suggests that the cell of origin of ccRCC may lie in PAX8-expressing Bowman capsule cells...
August 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28765068/5-trna-halves-are-dysregulated-in-clear-cell-renal-cell-carcinoma
#14
Chenming Zhao, Yuri Tolkach, Doris Schmidt, Glen Kristiansen, Stefan C Müller, Jörg Ellinger
PURPOSE: tRNA fragments are dysregulated in various malignancies. Our study was designed to determine the expression of four 5'-tRNA-halves in tissue and serum of clear cell renal cell carcinoma (ccRCC) patients. MATERIALS AND METHODS: Tissue and serum samples of patients with ccRCC and non-malignant disease were collected prospectively in our Biobank. We isolated total RNA from 95 ccRCC and 50 normal renal tissues as well as serum RNA from 27 patients with ccRCC and 13 with non-malignant urological diseases...
July 29, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28756136/addressing-the-best-treatment-for-non-clear-cell-renal-cell-carcinoma-a-meta-analysis-of-randomised-clinical-trials-comparing-vegfr-tkis-versus-mtori-targeted-therapies
#15
Chiara Ciccarese, Roberto Iacovelli, Matteo Brunelli, Francesco Massari, Davide Bimbatti, Emanuela Fantinel, Vincenzo De Marco, Antonio Benito Porcaro, Guido Martignoni, Walter Artibani, Giampaolo Tortora
AIM: Non-clear cell renal cell carcinoma (nccRCC) tumours include a heterogeneous group of malignancies that profoundly differ in terms of morphology, genetic profile, clinical behaviour and prognosis. The optimal treatment algorithm for nccRCC is still unknown and derived mainly from evidence available for ccRCC, being therefore represented by targeted agents against vascular endothelial growth factor and mammalian target of rapamycin (mTOR) pathways. We aimed to compare the efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKis) and mTOR inhibitors (mTORi) for the treatment of nccRCC patients...
July 27, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28754676/nsd1-inactivation-and-setd2-mutation-drive-a-convergence-toward-loss-of-function-of-h3k36-writers-in-clear-cell-renal-cell-carcinomas
#16
Xiaoping Su, Jianping Zhang, Roger Mouawad, Eva Compérat, Morgan Roupret, Frederick Allanic, Jérôme Parra, Marc-Olivier Bitker, Erika J Thompson, Banumathy Gowrishankar, Jane Houldsworth, John N Weinstein, Jörg Tost, Bradley M Broom, David Khayat, Jean-Philippe Spano, Nizar M Tannir, Gabriel G Malouf
Extensive dysregulation of chromatin-modifying genes in clear-cell renal cell carcinoma (ccRCC) has been uncovered through next-generation sequencing. However, a scientific understanding of the crosstalk between epigenetic and genomic aberrations remains limited. Here we identify three ccRCC epigenetic clusters, including a clear-cell CpG island methylator phenotype (C-CIMP) subgroup associated with promoter methylation of vascular endothelial growth factor receptor genes (FLT4, FLT1 and KDR). C-CIMP was furthermore characterized by silencing of genes related to vasculature development...
July 28, 2017: Cancer Research
https://www.readbyqxmd.com/read/28753793/micrornas-in-serum-exosomes-as-potential-biomarkers-in-clear-cell-renal-cell-carcinoma
#17
Wei Zhang, Maowei Ni, Ying Su, Hua Wang, Shaoxin Zhu, An Zhao, Guorong Li
BACKGROUND: Circulating microRNAs (miRNAs) in exosomes are emerging as clinically useful tools for cancer detection. However, little is known about their diagnostic impact in clear-cell renal cell carcinoma (ccRCC). OBJECTIVE: To investigate whether miRNAs in serum exosomes can serve as biomarkers in ccRCC. DESIGN, SETTING, AND PARTICIPANTS: Serum samples were obtained from 82 patients with ccRCC and 80 healthy volunteers. Exosomes were extracted and purified to selectively capture exosomes positive for tumor-associated epithelial cell adhesion molecule (EpCAM) via a magnetic bead technique...
October 14, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28753791/a-prospective-observational-study-for-assessment-and-outcome-association-of-circulating-endothelial-cells-in-clear-cell-renal-cell-carcinoma-patients-who-show-initial-benefit-from-first-line-treatment-the-circles-circulating-endothelial-cells-study-sogug-cec
#18
Jesús García-Donas, Luis Angel Leon, Emilio Esteban, Maria Jose Vidal-Mendez, Jose Angel Arranz, Xavier Garcia Del Muro, Laura Basterretxea, Aranzazu González Del Alba, Miguel Angel Climent, Juan Antonio Virizuela, Carlos Álvarez, Juan Sepúlveda, Urbano Anido, Carlos López, Maria Jose Ortiz-Morales, Xavier Pérez, Cristina Rodriguez-Antona, Juan Francisco Rodriguez-Moreno, Susana Hernando, Daniel Castellano
BACKGROUND: Markers able to predict the response to antiangiogenics in metastatic clear cell renal cell carcinoma (ccRCC) are not available. The development of new treatment options like immunotherapy are reaching the clinic; therefore, predictors of benefit from these different available treatments are increasingly needed. OBJECTIVE: In this study, we prospectively assessed the association of circulating endothelial cells (CECs) in peripheral blood with long-term benefit from first-line treatment in ccRCC...
October 4, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28753785/yrna-expression-profiles-are-altered-in-clear-cell-renal-cell-carcinoma
#19
Malin Nientiedt, Doris Schmidt, Glen Kristiansen, Stefan C Müller, Jörg Ellinger
BACKGROUND: Noncoding RNAs play an important role in human carcinogenesis. YRNAs, a novel class of noncoding RNAs, have been identified as biomarkers in breast cancer patients. OBJECTIVE: To test the hypothesis that YRNA expression is dysregulated in clear cell renal cell carcinoma (ccRCC). DESIGN, SETTING, AND PARTICIPANTS: We first measured the expression of all known YRNAs (hY1, hY3, hY4, and hY5) in a screening cohort (30 ccRCC and 15 normal renal tissues)...
August 23, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28749461/dnmt1-maintained-hypermethylation-of-kr%C3%A3-ppel-like-factor-5-involves-in-the-progression-of-clear-cell-renal-cell-carcinoma
#20
Rong-Jie Fu, Wei He, Xiao-Bo Wang, Lei Li, Huan-Bin Zhao, Xiao-Ye Liu, Zhi Pang, Guo-Qiang Chen, Lei Huang, Ke-Wen Zhao
Clear cell renal cell carcinoma (ccRCC) is the major subtype of renal cell carcinoma (RCC) that is resistant to conventional radiation and chemotherapy. It is a challenge to explore effective therapeutic targets and drugs for this kind of cancer. Transcription factor Krüppel-like factor 5 (KLF5) exerts diverse functions in various tumor types. By analyzing cohorts of the Cancer Genome Atlas (TCGA) data sets, we find that KLF5 expression is suppressed in ccRCC patients and higher level of KLF5 expression is associated with better prognostic outcome...
July 27, 2017: Cell Death & Disease
keyword
keyword
42598
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"